2024
From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
Walenczyk K, Singh A, Tong K, Burg M, Miller E. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal Of Health-System Pharmacy 2024, zxae183. PMID: 38963826, DOI: 10.1093/ajhp/zxae183.Peer-Reviewed Original ResearchPatient sociodemographic characteristicsATTR-CASociodemographic characteristicsSpecialty pharmacyPyrophosphate scintigraphyPopulation prevalence ratesEconomically disadvantaged areasTransthyretin cardiac amyloidosisBlack/African American raceReduce disparitiesPotential patient subgroupsPharmacy processesProportion of daysClinical pathwayCompare sociodemographicsDisadvantaged areasEquitable provisionTafamidis therapyCardiac amyloidosisTafamidis treatmentPrevalence ratesClinical programsAmerican racePatient subgroupsPosting manuscripts
2015
Ambulatory Medical Follow-Up in the Year After Surgery and Subsequent Survival in a National Cohort of Veterans Health Administration Surgical Patients
Schonberger RB, Dai F, Brandt C, Burg MM. Ambulatory Medical Follow-Up in the Year After Surgery and Subsequent Survival in a National Cohort of Veterans Health Administration Surgical Patients. Journal Of Cardiothoracic And Vascular Anesthesia 2015, 30: 671-679. PMID: 27021176, PMCID: PMC5499041, DOI: 10.1053/j.jvca.2015.12.019.Peer-Reviewed Original ResearchConceptsFirst postoperative yearPostoperative yearNational cohortPostsurgical yearSurgical patientsLong-term postoperative survivalVeterans Health Administration facilitiesFirst postsurgical yearRetrospective cohort studyPostoperative year 1Day of surgeryAmbulatory medical careHazard of deathPostoperative year 2Medical Follow-UpYear 2US veterans' hospitalsYear 1Cause mortalityPostoperative survivalCohort studyPatient subgroupsCare coordinationFollow-upUS veterans